HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin's fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.

By FiercePharma · Jun 5, 2026 · via FiercePharma
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
The WeekFierceBiotech ↗
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
On Thursday, the public had the first chance to air their grievances about the FDA's controversial Commissione…
Jun 5, 2026
White House Targets NIH Job Protections in Research Oversight Shake-Up
The WeekBriefing
White House Targets NIH Job Protections in Research Oversight Shake-Up
The Trump administration plans to strip job protections from around 8,000 NIH officials overseeing research gr…
Jun 5, 2026
The WeekDrug Channels ↗
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
Today's guest post comes from Stephen Hom, Co-Founder, EVP & Chief Operating Officer of RIS Rx. Drawing on RIS…
Jun 5, 2026